SCHEMBL3774594

SCHEMBL3774594

Cc1cc(C(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)oc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
LMNA P02545 1/20 0.44
KDM4E B2RXH2 4/20 0.44
HRH3 Q9Y5N1 2/20 0.43
L3MBTL3 Q96JM7 2/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SCN5A Q14524 2/20 0.41
SCN2A Q99250 2/20 0.41
SCN10A Q9Y5Y9 2/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
PARP1 P09874 1/20 0.40
HPGD P15428 1/20 0.40
CHRM2 P08172 1/20 0.39
CCR5 P51681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769139 0.82 ACACB (0.55) ALDH1A1L3MBTL1LMNAKDM4EL3MBTL3
SCHEMBL3765908 0.81 CCR5 (0.45) ALDH1A1L3MBTL1KDM4EHRH3L3MBTL3
SCHEMBL3762910 0.80 ALDH1A1 (0.54) ALDH1A1L3MBTL1HRH3L3MBTL3KMT2A
SCHEMBL3770028 0.79 HPGD (0.50) ALDH1A1L3MBTL1KDM4EHRH3L3MBTL3
SCHEMBL3763003 0.78 CCR5 (0.58) ALDH1A1KDM4EHRH3HTTNPSR1
SCHEMBL3773969 0.78 L3MBTL3 (0.49) ALDH1A1SMN1; SMN2GAAL3MBTL1KDM4E
SCHEMBL3769372 0.78 L3MBTL3 (0.49) ALDH1A1SMN1; SMN2L3MBTL1LMNAKDM4E
SCHEMBL3767212 0.77 HTT (0.56) ALDH1A1L3MBTL1KDM4EL3MBTL3HTT
SCHEMBL3770293 0.77 HRH3 (0.51) ALDH1A1L3MBTL1LMNAKDM4EHRH3
SCHEMBL3765235 0.77 HRH3 (0.51) ALDH1A1L3MBTL1KDM4EHRH3L3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885SMN1; SMN2 4282/4885GAA 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.